LigaChem Biosciences Inc. (KOSDAQ:141080) signed a contract on August 7 taking sole development and out-licensing rights to LNCB74, a B7-H4 antibody-drug conjugate it had been developing jointly with NextCure.
No news written yet.
| Period | 141080 | KOSDAQ | Difference |
|---|---|---|---|
| 1 week | -8.9% | -3.0% | -5.9% |
| 1 month | -16.3% | +4.2% | -20.5% |
| 3 months | -36.8% | -22.5% | -14.3% |
| 6 months | -43.2% | -16.9% | -26.3% |
| Year to date | -47.0% | -12.1% | -34.9% |
| 1 year | -38.3% | +1.0% | -39.3% |
Closed at 10% of the way from its 52-week low (₩77,900) to its 52-week high (₩213,500).
LigaChem Biosciences develops antibody-drug conjugates, medicines that attach a toxic payload to an antibody so the drug is delivered mainly to tumor cells. Rather than commercializing them alone, it licenses candidates to larger drugmakers, including deals with Johnson & Johnson and Amgen. That makes it a direct counterparty to US big pharma in one of oncology's most competitive fields. Its value rests on milestone payments and royalties from those partnerships rather than on products it sells itself.
| Sector | Biopharma | Employees | |
| Market | KOSDAQ | Founded | |
| Korean name | 리가켐바이오 | Head office |
| Symbol | Last Price |
|---|---|
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 145020Hugel, Inc. | ₩244,000 +1.5% |
| 302440SK Bioscience Co., Ltd. | ₩37,900 +0.4% |
| 009420Hanall Biopharma Co., Ltd. | ₩54,700 +1.5% |
| 310210Voronoi, Inc. | ₩153,000 +3.9% |
| 214370Caregen Co., Ltd. | ₩44,500 +1.5% |
| 347850D & D Pharmatech, Inc. | ₩49,200 +1.4% |